CymaBay Therapeutics, Inc.
Symbol: CBAY
NASDAQ
32.48
USDDzisiejsza cena rynkowa
-32.9591
Wskaźnik P/E
0.0000
Wskaźnik PEG
3.73B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
CymaBay Therapeutics, Inc. (CBAY) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1283.24 | 394.3 | 135.5 | 186.5 | ||||||||||||
balance-sheet.row.short-term-investments | 708.35 | 187.7 | 115.2 | 60.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 35.01 | 9.5 | 2.6 | 4.6 | ||||||||||||
balance-sheet.row.total-current-assets | 1318.25 | 403.8 | 138.1 | 191.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.83 | 5.7 | 0.9 | 1.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 22.36 | 22.4 | 0 | 8.1 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 9.26 | 2.8 | 2.9 | 1.7 | ||||||||||||
balance-sheet.row.total-non-current-assets | 39.45 | 30.9 | 3.8 | 11.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.account-payables | 12.78 | 3.8 | 1.1 | 2.7 | ||||||||||||
balance-sheet.row.short-term-debt | 11.12 | 10 | 0.7 | 0.6 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 397.14 | 99.2 | 90.3 | 51 | ||||||||||||
Deferred Revenue Non Current | 3.3 | 1.1 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -203.34 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 58.31 | 21.3 | 13.7 | 15.1 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 405.76 | 105.6 | 90.3 | 51 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 6.43 | 5.3 | 0.7 | 1.3 | ||||||||||||
balance-sheet.row.total-liab | 526.66 | 142.4 | 105.7 | 69.4 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.06 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3718.63 | -978.2 | -872.9 | -766.9 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.11 | 0.1 | -0.3 | 0 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4549.72 | 1270.3 | 909.3 | 899.8 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1357.7 | - | - | - | ||||||||||||
Total Investments | 730.71 | 210.1 | 115.2 | 68.8 | ||||||||||||
balance-sheet.row.total-debt | 413.58 | 114.5 | 90.9 | 51.6 | ||||||||||||
balance-sheet.row.net-debt | -161.31 | -92 | 70.6 | -74.2 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -105.37 | -105.4 | -106 | -90 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.77 | -2.7 | 0 | 0.6 | ||||||||||||
cash-flows.row.stock-based-compensation | 15.23 | 15.2 | 9.5 | 10 | ||||||||||||
cash-flows.row.change-in-working-capital | 5.63 | 5.6 | -2.3 | 6.4 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | 2.73 | 2.7 | -1.4 | 2.3 | ||||||||||||
cash-flows.row.other-working-capital | 2.9 | 2.9 | -0.9 | 4 | ||||||||||||
cash-flows.row.other-non-cash-items | 19.06 | 14 | 14 | 2.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -72.53 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.acquisitions-net | -2.11 | -7.9 | -0.9 | 0.6 | ||||||||||||
cash-flows.row.purchases-of-investments | -305.67 | -305.7 | -175 | -78.1 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 219.55 | 219.6 | 129.1 | 126.8 | ||||||||||||
cash-flows.row.other-investing-activites | 2.11 | 7.9 | 0.9 | -0.6 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -86.57 | -86.6 | -46 | 48.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -25 | -47.7 | ||||||||||||
cash-flows.row.common-stock-issued | 339.36 | 345.8 | -0.5 | 70.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -0.5 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -25 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 7.46 | 335.1 | 75.5 | 95.7 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 345.77 | 345.8 | 24.6 | 118.5 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 26.59 | -0.4 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 186.24 | 186.2 | -105.5 | 97.6 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 574.89 | 206.5 | 20.3 | 125.8 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 388.64 | 20.3 | 125.8 | 28.2 | ||||||||||||
cash-flows.row.operating-cash-flow | -72.53 | -72.5 | -84.1 | -69.4 | ||||||||||||
cash-flows.row.capital-expenditure | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.free-cash-flow | -72.98 | -73 | -84.2 | -69.5 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 31.07 | 31.1 | 0 | 0 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
income-statement-row.row.gross-profit | 30.39 | 30.4 | -0.7 | -0.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 80.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 51.95 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 132.7 | 132.1 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 132.75 | 132.8 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.interest-income | 13.49 | 13.5 | 2 | 0.2 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 3.18 | 0.7 | 2 | 0.9 | ||||||||||||
income-statement-row.row.ebitda-caps | -94.8 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -101.68 | -101.7 | -93.1 | -87.6 | ||||||||||||
income-statement-row.row.income-before-tax | -105.37 | -105.4 | -106 | -90 | ||||||||||||
income-statement-row.row.income-tax-expense | 11.99 | 0 | 12.9 | 2.6 | ||||||||||||
income-statement-row.row.net-income | -111.68 | -105.4 | -118.9 | -92.6 |
Często zadawane pytania
Ile wynosi CymaBay Therapeutics, Inc. (CBAY) aktywów ogółem?
CymaBay Therapeutics, Inc. (CBAY) całkowite aktywa to 434686000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 57000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.978.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -0.644.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -3.594.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -3.272.
Co to jest CymaBay Therapeutics, Inc. (CBAY) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -105370000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 114494000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 132071000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 206535000.000.